Explore the words cloud of the M6AQuantKit project. It provides you a very rough idea of what is the project "M6AQuantKit" about.
The following table provides information about the project.
WEIZMANN INSTITUTE OF SCIENCE
|Coordinator Country||Israel [IL]|
|Total cost||0 €|
|EC max contribution||150˙000 € (0%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2020-02-01 to 2021-07-31|
Take a look of project's partnership.
|1||WEIZMANN INSTITUTE OF SCIENCE||IL (REHOVOT)||coordinator||150˙000.00|
N6-Methyladenosine (m6A) plays fundamental roles in regulation of metabolism, stem cell self-renewal, and metastasis. Consistently its dysregulation is implicated in a variety of human cancers including leukemia, glioblastoma and hepatocellular carcinoma. Consequently, the potential of m6A both as a novel cancer diagnostic and as a drug target has raised immense interest in scientific community and industry. For unravelling m6A functions, for the development of therapeutics and for prioritizing diseases and disease states most likely to benefit from therapeutic targeting of the methylation complex, it is thus of crucial importance to be able to measure the levels at which m6A is present. In our ERC project we addressed this challenge and developed MAZTER-seq, a methodology for quantifying m6A levels relying on a methylation-sensitive ribonuclease (RNase), representing the first systematic approach for quantitative interrogating of m6A levels.
The goal of the project is to advance our approach as commercializable kit for quantitative profiling of m6A. In the PoC, we will develop multiplexed protocol of MAZTER-seq that allows the simultaneous processing and interrogation of multiple samples from low amounts of sample material. The kit, coupled with streamlined data analysis tool, addresses a major market need and exhibits significant added value for academic labs and the biotech & pharma industries targeting the methylation machinery, e.g. for creating novel RNA based therapeutics. Our readout from low-input material makes m6A monitoring amenable to patient samples, representing an unmet challenge across all our target market. Thus, our goal is to create a startup which harnesses the vast market potential. In the PoC, the commercialization considerations are advanced through actions such as, seeking market feedback, strengthening the IP position, defining the business strategy and planning business execution.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "M6AQUANTKIT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "M6AQUANTKIT" are provided by the European Opendata Portal: CORDIS opendata.